[go: up one dir, main page]

NZ738942B2 - Compound targeting il-23a and b-cell activating factor (baff) and uses thereof - Google Patents

Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Info

Publication number
NZ738942B2
NZ738942B2 NZ738942A NZ73894216A NZ738942B2 NZ 738942 B2 NZ738942 B2 NZ 738942B2 NZ 738942 A NZ738942 A NZ 738942A NZ 73894216 A NZ73894216 A NZ 73894216A NZ 738942 B2 NZ738942 B2 NZ 738942B2
Authority
NZ
New Zealand
Prior art keywords
seq
amino acid
polypeptide
acid sequence
polypeptides
Prior art date
Application number
NZ738942A
Other versions
NZ738942A (en
Inventor
Rachel Rebecca Barrett
Pankaj Gupta
Leslie S Johnson
Sarah Low
Qi Pan
Sanjaya Singh
Haixia Wu
Original Assignee
Boehringer Ingelheim International Gmbh
Macrogenics Inc
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Macrogenics Inc filed Critical Boehringer Ingelheim International Gmbh
Priority to NZ778160A priority Critical patent/NZ778160B2/en
Priority claimed from PCT/US2016/043267 external-priority patent/WO2017015433A2/en
Publication of NZ738942A publication Critical patent/NZ738942A/en
Publication of NZ738942B2 publication Critical patent/NZ738942B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Abstract

The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

Claims (20)

We Claim;
1. A compound comprising a first polypeptide and a second polypeptide, wherein: (A) said first polypeptide comprises: 5 10 15 20 25 30 35 (i) a light chain variable domain of a first immunoglobulin (VL1) specific for a first target protein; (ii) a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second target protein; and (iii) a hinge region, a heavy chain constant region 2 (CH2) and a heavy chain constant region 3 (CH3); and (B) said second polypeptide comprises: (i) a light chain variable domain of the second immunoglobulin (VL2) specific for said second target protein; (ii) a heavy chain variable domain of the first immunoglobulin (VH1) specific for said first target protein; wherein: a) said VL1 and VH1 associate to form a binding site that binds said first target protein; b) said VL2 and VH2 associate to form a binding site that binds said second target protein; c) said heavy chain constant region 2 (CH2) comprises a tyrosine at position 252, a threonine at position 254 and a glutamic acid a position 256, numbered according to the EU index as in Kabat; and d) said first target protein is BAFF and said second target protein is IL-23A or said first target protein is IL-23A and said second target protein is BAFF; and wherein: (i) said VL1 comprises SEQ ID NO:4, said VH1 comprises SEQ ID NO:3, said VL2 comprises SEQ ID NO:91 and said VH2 comprises SEQ ID NO:90 and further wherein said first polypeptide comprises a first linker between said VL1 and said VH2 and said second polypeptide comprises a second linker between said VL2 and said VH1 and said first polypeptide further comprises a heavy chain constant region 1 domain (CH1) and said second polypeptide further comprises a light chain constant region domain (CL), wherein said CL and said CH1 are associated together via a disulfide bond to form a C1 domain and said first polypeptide further comprises a third linker between said VH2 and said CH1 and said second polypeptide further comprises a fourth linker between said VH1 and said C, and the amino acid sequence of said hinge region, said heavy chain constant region 2 (CH2) and said heavy chain constant region 3 (CH3) is derived from a IgG1 or from a IgG4, wherein said first linker and said second linker both comprise the amino acid sequence GGGSGGGG (SEQ ID 124 NO:69).
2. A compound according to claim 1, wherein said third linker or said fourth linker or both comprise the amino acid sequence LGGGSG (SEQ ID NO:70).
3. 5 10 15 20 25 30 35 A compound according to claim 1, wherein said heavy chain constant region 2 (CH2) comprises an alanine at positions 234 and an alanine at position 235, numbered according to the EU index as in Kabat or said hinge region comprises the amino acid sequence EPKSCDKTHTCPPCP (SEQ ID NO:76), the amino acid sequence LEPKSSDKTHTCPPCP (SEQ ID NO: 130) or the amino acid sequence ESKYGPPCPPCP (SEQ ID NO: 134).
4.
5. A compound according to claim 1, wherein: (i) said first polypeptide comprises the amino acid sequence of SEQ ID NO:45 and said second polypeptide comprises the amino acid sequence of SEQ ID NO:46; or (ii) said first polypeptide comprises the amino acid sequence of SEQ ID NO:47 and said second polypeptide comprises the amino acid sequence of SEQ ID NO:48; or (iii) said first polypeptide comprises the amino acid sequence of SEQ ID NO:49 and said second polypeptide comprises the amino acid sequence of SEQ ID NO:50; or (iv) said first polypeptide comprises the amino acid sequence of SEQ ID NO:51 and said second polypeptide comprises the amino acid sequence of SEQ ID NO:52. A compound according to claim 1, wherein said first polypeptide comprises the amino acid sequence of SEQ ID NO:49 and said second polypeptide comprises the amino acid sequence of SEQ ID NO:50.
6. A compound according to claim 1, wherein said compound comprises two of said first polypeptides and two of said second polypeptides, wherein each of said first polypeptides comprises a CH1, hinge, a CH2 and a CH3 and each of said second polypeptides comprises a CL and further wherein the hinge, CH2 and CH3 of one of the first polypeptides associates with the hinge, CH2 and CH3 of the other of the first polypeptides and the CH1 of each said first polypeptides associates with the CL of one said second polypeptides to form a tetravalent molecule (xi) one according to claim 1 or claim 2(i) to (x), wherein said compound comprises two said first polypeptides and two said second polypeptides, wherein said two first polypeptides are associated together via at least one disulfide bond.
7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6.
8. Use of a compound according to any one of claims 1 to 6, or a pharmaceutical composition comprising said compound in the preparation of a medicament for treatment of an autoimmune disease in a subject in need thereof.
9. Use of a compound according to any one of claims 1 to 6, or a pharmaceutical composition comprising said compound in the preparation of a medicament for treatment of an inflammatory disease in a subject in need thereof. 125
10. Use of a compound according to any one of claims 1 to 6, in the preparation of a medicament.
11. 5 A nucleic acid selected from the following: (i) one comprising a nucleotide sequence encoding a polypeptide according to any one of claims 1 to 6; (ii) a vector comprising a nucleic acid according to (i); or (iii) a vector comprising a nucleic acid according to (i) further comprising a promoter operably linked to said nucleic acid. 10 15 20 25 30
12. A cell comprising a nucleic acid or a vector according to claim 11(i) to (iii), with the proviso that said cell is not present in a human being.
13. An in vitro method of producing a polypeptide according to any one of claims 1 to 6, comprising obtaining a cell according to claim 12, expressing said nucleic acid in a cell culture comprising said cell and isolating the expressed polypeptide from the cell or cell culture.
14. Use according to claim 10 or 11, wherein the autoimmune or an inflammatory disease comprises systemic lupus erythematosus (SLE), systemic lupus erythematosus with kidney involvement, Lupus Nephritis (LN), ANCA-associated vasculitis (AAV), primary Sjögren’s syndrome (pSS), chronic graft versus host disease (cGVHD), systemic sclerosis (SSc), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PA).
15. The compound of any one of claims 1-6 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
16. The pharmaceutical composition of claim 7 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
17. The use of any one of claims 8-10 and 14 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
18. The nucleic acid of claim 11 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
19. The cell of claim 12 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
20. The method of claim 13 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
NZ738942A 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof NZ738942B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ778160A NZ778160B2 (en) 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US201662355302P 2016-06-27 2016-06-27
PCT/US2016/043267 WO2017015433A2 (en) 2015-07-23 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Publications (2)

Publication Number Publication Date
NZ738942A NZ738942A (en) 2025-05-02
NZ738942B2 true NZ738942B2 (en) 2025-08-05

Family

ID=

Similar Documents

Publication Publication Date Title
JP2018527323A5 (en)
Gunasekaran et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG
TWI806961B (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
KR102629905B1 (en) Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
WO2019109876A1 (en) Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
WO2019190327A2 (en) Multivalent antibody
DK2632946T3 (en) PROCEDURE FOR MANUFACTURING VARIABLE IMMUNGLOBULIN SINGLE DOMAINS
US11319378B2 (en) Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
KR20140112515A (en) Light chain-bridged bispecific antibody
HK1207575A1 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
CN109641949B (en) Multispecific antibodies that promote selective light chain pairing
WO2011079308A2 (en) Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US10329350B2 (en) Method for producing a multivalent fab fragment with collagen-like peptide
CN105916883B (en) Bifunctional fusion protein and preparation method and use thereof
JP2024517907A (en) Antigen-binding molecules
NZ738942B2 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
NZ738942A (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
TW202130365A (en) Multi-specific antibody with binding specificity for human il-13 and il-17
CN112930358B (en) anti-TNF alpha/anti-IL-17A natural antibody structure-like heterodimer form bispecific antibody and preparation thereof
NZ778160B2 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
NZ766849B2 (en) Compound targeting il-23a and tnf-alpha and uses thereof
NZ730014B2 (en) Compound targeting il-23a and tnf-alpha and uses thereof
NZ766849A (en) Compound targeting il-23a and tnf-alpha and uses thereof
CN116670289A (en) Anti-PD-L1/anti-CD47 natural antibody structure-like heterodimer bispecific antibody and its preparation
RU2021103120A (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DESIGNED CONSTRUCTS BASED ON Fc ANTIGEN BINDING DOMAIN